AIM ImmunoTech Inc.
Follow $AIM
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AIM by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is AIM moving today?
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
AIM overview
Related filings and maps
Congress activity in AIM
No receipt-qualified filings found.
AIM contract awards, year to date.
Public federal awards linked to this ticker.
AIM lobbying filings, year to date.
Registered lobbying filings matched to AIM ImmunoTech Inc..